Intercomparison of Monte Carlo calculated dose enhancement ratios for gold nanoparticles irradiated by X-rays: Assessing the uncertainty and correct methodology for extended beams.
Dose enhancement
Gold nanoparticles
Targeted radiotherapy
X-rays
Journal
Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics (AIFB)
ISSN: 1724-191X
Titre abrégé: Phys Med
Pays: Italy
ID NLM: 9302888
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
09
10
2020
revised:
24
02
2021
accepted:
01
03
2021
pubmed:
27
3
2021
medline:
29
6
2021
entrez:
26
3
2021
Statut:
ppublish
Résumé
Results of a Monte Carlo code intercomparison exercise for simulations of the dose enhancement from a gold nanoparticle (GNP) irradiated by X-rays have been recently reported. To highlight potential differences between codes, the dose enhancement ratios (DERs) were shown for the narrow-beam geometry used in the simulations, which leads to values significantly higher than unity over distances in the order of several tens of micrometers from the GNP surface. As it has come to our attention that the figures in our paper have given rise to misinterpretation as showing 'the' DERs of GNPs under diagnostic X-ray irradiation, this article presents estimates of the DERs that would have been obtained with realistic radiation field extensions and presence of secondary particle equilibrium (SPE). These DER values are much smaller than those for a narrow-beam irradiation shown in our paper, and significant dose enhancement is only found within a few hundred nanometers around the GNP. The approach used to obtain these estimates required the development of a methodology to identify and, where possible, correct results from simulations whose implementation deviated from the initial exercise definition. Based on this methodology, literature on Monte Carlo simulated DERs has been critically assessed.
Identifiants
pubmed: 33766478
pii: S1120-1797(21)00121-6
doi: 10.1016/j.ejmp.2021.03.005
pmc: PMC8187310
mid: NIHMS1683217
pii:
doi:
Substances chimiques
Gold
7440-57-5
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
241-253Subventions
Organisme : NCI NIH HHS
ID : R01 CA187003
Pays : United States
Informations de copyright
Copyright © 2021 Associazione Italiana di Fisica Medica. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Phys Med Biol. 2004 Sep 21;49(18):N309-15
pubmed: 15509078
Radiother Oncol. 2011 Sep;100(3):412-6
pubmed: 21924786
Med Phys. 2013 Jul;40(7):071710
pubmed: 23822414
Phys Med Biol. 2014 Dec 21;59(24):7675-89
pubmed: 25415297
Br J Radiol. 2012 Feb;85(1010):101-13
pubmed: 22010024
Phys Med. 2019 Jul;63:98-104
pubmed: 31221415
Med Phys. 2021 Apr;48(4):1874-1883
pubmed: 33150620
Br J Radiol. 2016;89(1059):20150200
pubmed: 26642305
Phys Med Biol. 2012 Apr 21;57(8):2117-36
pubmed: 22451262
Phys Med Biol. 2016 Dec 02;61(24):8839-8853
pubmed: 27910829
Phys Med Biol. 2005 Aug 7;50(15):N163-73
pubmed: 16030374
Cancer Nanotechnol. 2017;8(1):9
pubmed: 29213338
Nanomedicine (Lond). 2018 Apr;13(8):809-823
pubmed: 29485321
Phys Med. 2020 Dec;80:57-64
pubmed: 33115700
Phys Med Biol. 2018 Jan 09;63(2):02TR01
pubmed: 29125831
Phys Med. 2020 Jan;69:147-163
pubmed: 31918367
Med Phys. 2012 Jun;39(6):3509-19
pubmed: 22755731
J Radiol Prot. 2021 Jan 06;:
pubmed: 33406511
Rep Pract Oncol Radiother. 2010 Oct 08;15(6):176-80
pubmed: 24376946
Int J Radiat Oncol Biol Phys. 2016 Jan 1;94(1):189-205
pubmed: 26700713
J ICRU. 2011 Apr;11(1):1-31
pubmed: 24174259
Phys Med. 2019 Dec;68:1-9
pubmed: 31715285
Bioimpacts. 2013;3(1):29-35
pubmed: 23678467
Phys Med Biol. 2017 Mar 7;62(5):1935-1948
pubmed: 28140338
Med Phys. 2011 Feb;38(2):624-31
pubmed: 21452700
Med Phys. 2015 Oct;42(10):5890-902
pubmed: 26429263
Transl Cancer Res. 2013 Aug 1;2(4):280-291
pubmed: 25429358
Sci Rep. 2020 Jul 21;10(1):12096
pubmed: 32694592
Adv Drug Deliv Rev. 2017 Jan 15;109:84-101
pubmed: 26712711
Ann ICRP. 2018 Oct;47(3-4):20-34
pubmed: 29664324
Radiother Oncol. 2017 Sep;124(3):344-356
pubmed: 28784439
Nanomedicine (Lond). 2013 Oct;8(10):1601-9
pubmed: 23265347
Phys Med Biol. 2016 Mar 7;61(5):2014-24
pubmed: 26895030
Phys Med. 2019 Apr;60:22-29
pubmed: 31000082
Phys Med Biol. 2019 Aug 07;64(15):155016
pubmed: 31300616
Med Phys. 2010 Jul;37(7):3809-16
pubmed: 20831089
Phys Med Biol. 2013 Nov 21;58(22):7961-77
pubmed: 24169737
Sci Rep. 2011;1:18
pubmed: 22355537
J Cancer Res Ther. 2015 Jan-Mar;11(1):94-7
pubmed: 25879344